Trial Profile
An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms NTHI MCAT-002
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 03 Sep 2022 Results assessing the efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations, published in the Vaccine.
- 13 Apr 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.